2018
To chelate or not to chelate in MDS: That is the question!
Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews 2018, 32: 368-377. PMID: 29602612, DOI: 10.1016/j.blre.2018.03.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsChelation TherapyClinical Decision-MakingDisease ManagementHumansIron Chelating AgentsIron OverloadMyelodysplastic SyndromesConceptsIron chelation therapyMyelodysplastic syndromeIron overloadMDS patientsChronic transfusion supportAcute myeloid leukemiaBone marrow failureDisease-related alterationsTransfusion supportSurvival impactRandomized trialsInferior outcomesMyeloid leukemiaChelation therapyClinical consequencesMarrow failurePatientsHeterogeneous groupIron metabolismTherapyInherent risksSyndromePhysical manifestationsLeukemiaHemopathies
2017
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews In Oncology/Hematology 2017, 117: 57-66. PMID: 28807236, DOI: 10.1016/j.critrevonc.2017.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsChelation TherapyHumansIron Chelating AgentsIron OverloadMyelodysplastic SyndromesPrognosisConceptsIron chelation therapyIron overloadMyelodysplastic syndromeFrequent red blood cell transfusionsLower-risk myelodysplastic syndromesRed blood cell transfusionLow-risk MDS patientsHeterogeneous hematopoietic neoplasmsRandomized trial evidenceBlood cell transfusionAcute myeloid leukemiaTissue iron depositionCell transfusionSupportive careMDS patientsTrial evidenceMyeloid leukemiaChelation therapyThalassemia patientsIneffective erythropoiesisBetter survivalPatientsEndocrine toxicityIron depositionHematopoietic neoplasms